Real-World Evidence of Transcutaneous Afferent Patterned Stimulation for Essential Tremor.

Autor:	Brillman S; Parkinson's Disease and Movement Disorders Center of Silicon Valley, Palo Alto, CA, USA., Colletta K; Department of Neurology, Edward Hines Jr. VA Hospital, Hines, IL, USA., Borucki S; Department of Neurology, Temple VA Medical Center, Temple, TX, USA., Lin PT; Valley Parkinson Clinic, Los Gatos, CA, USA., Waln O; Houston Methodist Neurological Institute, Houston, TX, USA., Petrossian M; Pacific Neuroscience Institute, Pacific Movement Disorders Center, Santa Monica, CA, USA., Khemani P; Swedish Neuroscience Institute, Seattle, WA, USA., Rajagopal A; Cala Health Inc, San Mateo, CA, USA., Rosenbluth KH; Cala Health Inc, San Mateo, CA, USA., Khosla D; Cala Health Inc, San Mateo, CA, USA.
Jazyk:	angličtina
Zdroj:	Tremor and other hyperkinetic movements (New York, N.Y.) [Tremor Other Hyperkinet Mov (N Y)] 2022 Sep 01; Vol. 12, pp. 27. Date of Electronic Publication: 2022 Sep 01 (Print Publication: 2022).
DOI:	10.5334/tohm.715
Abstrakt:	Background: Transcutaneous afferent patterned stimulation (TAPS) is a prescription, wrist-worn device-delivered, non-invasive neuromodulation therapy for treatment of hand tremor in patients with essential tremor (ET). This retrospective post-market surveillance study evaluated real-world effectiveness of TAPS from patients using therapy on-demand for at least 90 days between August 2019 through June 2021. Methods: Demographics were summarized from TAPS prescriptions received from the patient's healthcare provider. Therapy usage and effectiveness were analyzed from device logs, which included tremor measurements from onboard motion sensors. Tremor history and patient-reported outcomes were assessed from a voluntary survey. Results: A total of 321 patients (average age 71 years, 32% female) met the criteria for this analysis, 216 of whom had tremor measurements available for analysis and 69 of whom completed the survey. Total usage period ranged from 90 to 663 days, with 28% of patients using the device for over one year. Patients used therapy 5.4 ± 4.5 (mean ± 1 standard deviation) times per week. TAPS reduced tremor power by 71% (geometric mean) across all sessions, with 59% of patients experiencing >50% tremor reduction after their sessions. Eighty-four percent (84%) of patients who returned the voluntary survey reported improvement in at least one of eating, drinking, or writing, and 65% of patients reported improvement in quality of life. Self-reported device-related safety complaints were consistent with adverse events in prior clinical trials. Discussion: Real-world evidence is consistent with prior clinical trials and confirms TAPS provides safe and effective tremor control for many patients with ET. Future work assessing multi-year safety and effectiveness would be valuable to extend these data. Competing Interests: KH Rosenbluth and D Khosla are employees of Cala Health. A Rajagopal is a former employee of Cala Health. S Brillman and O Waln served as consultants for Cala Health. P Khemani served as an advisor and speaker for Cala Health, as well as for Boston Scientific, GE DaTScan, Abbvie, TEVA, Amneal, Neurocrine, and Acorda. K Colletta, S Borucki, PT Lin, and M Petrossian report no disclosures relevant to the manuscript. (Copyright: © 2022 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu